Skip to Main Content
Table 1

Risk of breast cancer by CYP1A1-exon7 polymorphism and plasma levels of lipid-adjusted PCBs among all women and postmenopausal women only

CYP1A1 genotypeTertile PCBsa (cut-offs μg/g)CasesControlsRR (95% CI)Multivariate RRb (95% CI)
Postmenopausal women (293 case/control pairs)      
 WT/WT 1 (0.13–0.47) 84 81 1.00 1.00 
 WT/WT 2 (0.47–0.67) 82 87 0.91 (0.59–1.42) 1.00 (0.63–1.60) 
 WT/WT 3 (0.67–1.99) 84 90 0.90 (0.55–1.48) 0.97 (0.57–1.67) 
 Variantsc 1 (0.13–0.47) 16 0.53 (0.21–1.31) 0.52 (0.20–1.36) 
 Variants 2 (0.47–0.67) 15 12 1.19 (0.51–2.78) 1.29 (0.51–3.21) 
 Variants 3 (0.67–1.99) 19 2.76 (1.04–7.35) 2.78 (0.99–7.82) 
 Test for interactiond    0.03 0.05 
All women (367 case/control pairs)      
 WT/WT 1 (0.13–0.46) 113 101 1.00 1.00 
 WT/WT 2 (0.46–0.65) 100 103 0.86 (0.58–1.28) 0.93 (0.60–1.43) 
 WT/WT 3 (0.65–1.99) 103 107 0.84 (0.54–1.32) 0.89 (0.55–1.45) 
 Variantsb 1 (0.13–0.46) 12 21 0.49 (0.23–1.07) 0.54 (0.24–1.22) 
 Variants 2 (0.46–0.65) 18 21 0.72 (0.36–1.46) 0.76 (0.35–1.63) 
 Variants 3 (0.65–1.99) 21 14 1.33 (0.62–2.83) 1.36 (0.60–3.12) 
 Test for interaction    0.10 0.19 
CYP1A1 genotypeTertile PCBsa (cut-offs μg/g)CasesControlsRR (95% CI)Multivariate RRb (95% CI)
Postmenopausal women (293 case/control pairs)      
 WT/WT 1 (0.13–0.47) 84 81 1.00 1.00 
 WT/WT 2 (0.47–0.67) 82 87 0.91 (0.59–1.42) 1.00 (0.63–1.60) 
 WT/WT 3 (0.67–1.99) 84 90 0.90 (0.55–1.48) 0.97 (0.57–1.67) 
 Variantsc 1 (0.13–0.47) 16 0.53 (0.21–1.31) 0.52 (0.20–1.36) 
 Variants 2 (0.47–0.67) 15 12 1.19 (0.51–2.78) 1.29 (0.51–3.21) 
 Variants 3 (0.67–1.99) 19 2.76 (1.04–7.35) 2.78 (0.99–7.82) 
 Test for interactiond    0.03 0.05 
All women (367 case/control pairs)      
 WT/WT 1 (0.13–0.46) 113 101 1.00 1.00 
 WT/WT 2 (0.46–0.65) 100 103 0.86 (0.58–1.28) 0.93 (0.60–1.43) 
 WT/WT 3 (0.65–1.99) 103 107 0.84 (0.54–1.32) 0.89 (0.55–1.45) 
 Variantsb 1 (0.13–0.46) 12 21 0.49 (0.23–1.07) 0.54 (0.24–1.22) 
 Variants 2 (0.46–0.65) 18 21 0.72 (0.36–1.46) 0.76 (0.35–1.63) 
 Variants 3 (0.65–1.99) 21 14 1.33 (0.62–2.83) 1.36 (0.60–3.12) 
 Test for interaction    0.10 0.19 
a

Cut-offs for tertiles based on the appropriate control distribution, all women or postmenopausal only depending on the analysis.

b

RR adjusted for history of breast cancer in mother or a sister, a history of benign breast disease, age at menarche (<12 years, 12 years, >12 years), body mass index (<25, 25–29, 30+ kg/m2), number of children, and age at birth of first child (nulliparous, 1–2 children and age ≤24 at first birth, 1–2 children and age >24 at first birth, ≥3 children and age ≤24 at first birth, and ≥3 children and age >24 at first birth), and duration of lactation (0, 1–6 months, and >6 months).

c

Variants are all women who are either heterozygous or homozygous for the variant allele.

d

Test for interaction, likelihood ratio test comparing model with cross-classified variables with model with main effects only.

Close Modal

or Create an Account

Close Modal
Close Modal